ACC.25: Focus on ATTR-CM
Advertisement
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM.
A multifaceted approach is necessary to reduce the deaths of smoking-related aortic aneurysms.
Many preschool-aged children with congenital heart conditions are not on track for school readiness.
Sudden cardiac death increases amid lower daily temperatures.
Acoramidis therapy significantly increases serum transthyretin in people with ATTR-CM compared with tafamidis.
Patients with single ventricle heart disease commonly have mental health diagnoses.
Acoramidis therapy induces a significant increase in serum transthyretin, which is typically lower in ATTRv-CM.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.